Prescription practices and empirical efficacy of psychopharmacologic treatments for pediatric major depressive disorder.
Limited research on pharmacologic treatments for pediatric major depressive disorder (MDD) exists. Prescription practices data for MDD from 1,209 American Academy of Child and Adolescent Psychiatry members collected in 1998 are compared to the current empirical support for this treatment approach. Results indicated that psychiatrists have willingly used medication as a first-line treatment for MDD in children under age 7, despite a paucity of research support for this practice. Recent warnings regarding the use of selective serotonin reuptake inhibitors warrant the need to reexamine current prescription practices of psychiatric care providers for children diagnosed with MDD.